Apimeds Pharmaceuticals US, Inc. (APUS)

Apimeds Pharmaceuticals US, Inc. (APUS) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector listed on the NYSE MKT.

As of Oct 23, 2026: market cap $6.1M; returns 1 day -8.5%, 1 week -28.5%, 1 year -83.3%.

Apimeds Pharmaceuticals US, Inc. (APUS) is a clinical-stage biopharmaceutical company focused on developing innovative therapies derived from bee venom peptides and apitherapy compounds for treating inflammatory and autoimmune diseases.

Groups APUS belongs to

• Recent Reverse Splits
• Clinical Stage Biopharma
• Biotechnology
• Biopharmaceutical
• Clinical Stage
• Autoimmune Diseases
• Rheumatoid Arthritis
• Dermatology
• Healthcare
• R&D

APUS financial model: income statement, cash flow and balance sheet